Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides
- Author
- HENRY, S. P1 ; MONTEITH, D1 ; LEVIN, A. A1
[1] Department of Toxicology, Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, United States - Source
Anti-cancer drug design. 1997, Vol 12, Num 5, pp 395-408 ; ref : 1 p.3/4
- ISSN
- 0266-9536
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Adhérence Aire sous la courbe Animal Anticancéreux Antiinflammatoire Article synthèse Cinétique Comparaison interspécifique Foie Homme Immunostimulation Inhibiteur enzyme Inhibiteur Oligodésoxyribonucléotide Oligonucléotide antisens Pharmacocinétique Posologie Protein kinase C Protéine CAM Prédiction Rein Singe Subchronique Système immunitaire Thiophosphate organique Toxicité Toxicocinétique Voie intraveineuse ISIS 2302 ISIS 3521 ISIS 5132 Appareil digestif pathologie Appareil urinaire pathologie Enzyme Hémopathie Immunopathologie Mammalia Primates Transferases Vertebrata
- Keyword (en)
- Adhesion Area under the curve Animal Antineoplastic agent Antiinflammatory agent Review Kinetics Interspecific comparison Liver Human Immunostimulation Enzyme inhibitor Inhibitor Oligodeoxyribonucleotide Antisense oligonucleotide Pharmacokinetics Posology Protein kinase C Cell adhesion molecule Prediction Kidney Monkey Subchronic Immune system Organic thiophosphate Toxicity Toxicokinetics Intravenous administration Digestive diseases Urinary system disease Enzyme Hemopathy Immunopathology Mammalia Primates Transferases Vertebrata
- Keyword (es)
- Adherencia Area debajo de la curva Animal Anticanceroso Antiinflamatorio Artículo síntesis Cinética Comparación interespecífica Hígado Hombre Inmunoestimulación Inhibidor enzima Inhibidor Oligodesoxirribonucleótido Oligonucleótido antisentido Farmacocinética Posología Protein kinase C Proteína CAM Predicción Riñón Mono Subcrónico Sistema inmunitario Tiofosfato orgánico Toxicidad Toxicocinética Vía intravenosa Aparato digestivo patología Aparato urinario patología Enzima Hemopatía Inmunopatología Mammalia Primates Transferases Vertebrata
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U10 Miscellaneous (drug allergy, mutagens, teratogens...)
- Discipline
- Drugs toxicity and drug intoxications Toxicology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 2743782
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"395\";s:8:\"\u0000*\u0000epage\";s:3:\"408\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:11:\"MONTEITH, D\";i:1;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"395\";s:8:\"\u0000*\u0000epage\";s:3:\"408\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:11:\"MONTEITH, D\";i:1;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"395\";s:8:\"\u0000*\u0000epage\";s:3:\"408\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:11:\"MONTEITH, D\";i:1;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"395\";s:8:\"\u0000*\u0000epage\";s:3:\"408\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:11:\"MONTEITH, D\";i:1;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"395\";s:8:\"\u0000*\u0000epage\";s:3:\"408\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:11:\"MONTEITH, D\";i:1;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotides\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
